PetVivo Holdings, Inc. (NASDAQ:PETV, PETVW))))) (the "Company" or "PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced that the Company will be releasing the results of a clinical study conducted by Ethos Veterinary Health at the American College of Veterinary Surgeons ("ACVS") annual conference on the completion of a clinical study, which examined the benefit and tolerability of an intra-articular injection of a collagen-elastin biomaterial (i.e. Spryng™ with OsteoCushion™ Technology) into the stifle joint of dogs with suspected cruciate ligament rupture. Dr. Erik Kleeman, DVM will be presenting the poster at ACVS.

 

"We were pleased to have the final results of the Spryng clinical study offered in a poster presentation at the ACVS annual conference as this data demonstrates the efficacy of this product as an excellent, non-invasive alternative for patients with cranial cruciate disease," said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "We continue to strive to provide data demonstrating that Spryng is a viable tool to use in the management of joint related afflictions and thereby enhancing the lives of companion animals and their owners."

Spryng is an injectable veterinary medical device comprised of millions of micronized extracellular matrix particles, which are derived from natural components, including collagen and elastin. OsteoCushion Technology provides both reinforcing natural joint support to augment and/or reinforce missing and damaged cartilage, as well as delivers natural scaffolding to help address tissue defects. These attributes offer a great solution to manage lameness and joint afflictions, such as osteoarthritis, for companion animals in a simple in-clinic administration.

The dogs enrolled in this study had been diagnosed with a partial or complete cranial cruciate ligament tear (similar to an ACL tear in humans). The primary endpoint of the study was to demonstrate whether there was a significant reduction in pain after Spryng injection, as measured by the modified Glasgow Composite Pain Scale; a significant reduction of pain by 25% or greater would be considered a beneficial response. There were significant improvements in all of the primary and secondary clinical variables throughout the study period (pain, lameness, quality of life scoring). In summary, this study demonstrates that Spryng™ is a reasonable, non-invasive alternative for patients with cranial cruciate disease ("CCD") when patient and/or owner factors preclude surgical intervention. To view the poster presentation and a video interview of Dr. Kleeman discussing the clinical study presented at the ACVS annual conference please visit the following:

https://www.sprynghealth.com/acvs-2023-poster-presentation?fbclid=IwAR3VuoyNy8wdqFnnArkNsjI-HzTXtXo49jDI3WOn8-835jMBf5spy451O6E